Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trilaciclib - G1 Therapeutics

Next Previous
Drug Profile

Trilaciclib - G1 Therapeutics

Alternative Names: COSELA; G1T 28; G1T28-1

Latest Information Update: 23 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator G1 Therapeutics
  • Developer Boehringer Ingelheim; G1 Therapeutics; Quantum Leap Healthcare Collaborative; Simcere Pharmaceutical Group
  • Class Amines; Antineoplastics; Aza compounds; Chemoprotectants; Cyclohexanes; Ketones; Piperazines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Radioprotectives; Small molecules; Spiro compounds
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Myelosuppression
  • Phase III Small cell lung cancer; Triple negative breast cancer
  • Phase II Bladder cancer; Breast cancer; Non-small cell lung cancer
  • No development reported Cancer
  • Discontinued Colorectal cancer

Most Recent Events

  • 16 Mar 2026 Pharmacosmos plans a phase III trial for Myelosuppression (Chemotherapy-induced; Prevention ) (IV, Infusion) in March 2026 (NCT07473128 )
  • 09 Feb 2026 Trilaciclib is still in phase III PRESERVE 2 trial in Triple-negative-breast-cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in France, USA, Australia, Bulgaria, China, France, Georgia, Moldova, Poland, Spain, Russia, Serbia and Ukraine (IV) (NCT04799249)
  • 09 Feb 2026 Discontinued - Phase-III for Colorectal cancer (Metastatic disease, First-line therapy, Inoperable/Unresectable) in Ukraine, Slovakia, Italy, Hungary, USA, Spain, Poland, China and United Kingdom (IV) (Pharmacosmos pipeline; February 2026) (NCT04607668)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top